ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310

Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level);

No cases of amyloid-related imaging abnormalities (ARIA) observed to date;

Read more at globenewswire.com